Literature DB >> 24945731

MicroRNA-141 promotes the proliferation of non-small cell lung cancer cells by regulating expression of PHLPP1 and PHLPP2.

Zhoufang Mei1, Yanchao He1, Jingjing Feng1, Jindong Shi1, Yong Du1, Ling Qian1, Qihui Huang1, Zhijun Jie2.   

Abstract

The dysregulation of microRNAs (miRNAs) is crucially implicated in the development of various cancers. In this study, we explored the biological role of miR-141 in non-small cell lung cancer (NSCLC). miR-141 expression was significantly up-regulated in NSCLC tissues, and its overexpression accelerated NSCLC cell proliferation in vitro and tumor growth in vivo. We subsequently identified the antagonists of PI3K/AKT signaling, PH domain leucine-rich-repeats protein phosphatase 1 (PHLPP1) and PHLPP2, as direct targets of miR-141. Re-introduction of PHLPP1 and PHLPP2 abrogated miR-141-induced proliferation of NSCLC cells. Together, the results of this study suggest that miR-141 and its targets PHLPP1 and PHLPP2 play critical roles in NSCLC tumorigenesis, and provide potential therapeutic targets for NSCLC treatment.
Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MicroRNA-141; Non-small cell lung cancer; PH domain leucine-rich-repeats protein phosphatase 1; PH domain leucine-rich-repeats protein phosphatase 2; Proliferation

Mesh:

Substances:

Year:  2014        PMID: 24945731     DOI: 10.1016/j.febslet.2014.06.020

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  33 in total

1.  miR-3117 regulates hepatocellular carcinoma cell proliferation by targeting PHLPPL.

Authors:  Xia Cui; Qingyan Li; Yukai He
Journal:  Mol Cell Biochem       Date:  2016-11-07       Impact factor: 3.396

2.  miR-141-3p functions as a tumor suppressor modulating activating transcription factor 5 in glioma.

Authors:  Mengyuan Wang; Ming Hu; Zhaohua Li; Dongmeng Qian; Bin Wang; David X Liu
Journal:  Biochem Biophys Res Commun       Date:  2017-06-07       Impact factor: 3.575

3.  Arsenic-exposed Keratinocytes Exhibit Differential microRNAs Expression Profile; Potential Implication of miR-21, miR-200a and miR-141 in Melanoma Pathway.

Authors:  Horacio Gonzalez; Carolina Lema; Robert A Kirken; Rosa A Maldonado; Armando Varela-Ramirez; Renato J Aguilera
Journal:  Clin Cancer Drugs       Date:  2015

4.  MicroRNAs aid the assessment of programmed death ligand 1 expression in patients with non-small cell lung cancer.

Authors:  Anna Grenda; Marcin Nicoś; Michał Szczyrek; Paweł Krawczyk; Tomasz Kucharczyk; Bożena Jarosz; Juliusz Pankowski; Marek Sawicki; Justyna Szumiło; Paulina Bukała; Janusz Milanowski
Journal:  Oncol Lett       Date:  2019-04-03       Impact factor: 2.967

5.  MiR-25 is up-regulated in non-small cell lung cancer and promotes cell proliferation and motility by targeting FBXW7.

Authors:  Jie Xiang; Jun-Biao Hang; Jia-Ming Che; He-Cheng Li
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

6.  Integrative analysis reveals disrupted pathways regulated by microRNAs in cancer.

Authors:  Gary Wilk; Rosemary Braun
Journal:  Nucleic Acids Res       Date:  2018-02-16       Impact factor: 16.971

7.  Prognostic role of microRNA-31 in various cancers: a meta-analysis.

Authors:  Shuwei Wang; Jun Hu; Dongsheng Zhang; Juan Li; Qiang Fei; Yueming Sun
Journal:  Tumour Biol       Date:  2014-08-20

8.  MiR-145 acts as a metastasis suppressor by targeting metadherin in lung cancer.

Authors:  Mingzhi Wang; Jianhua Wang; Jianming Deng; Xuejun Li; Weiguang Long; Yongmei Chang
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

Review 9.  MicroRNA as tools and therapeutics in lung cancer.

Authors:  Jennifer F Barger; S Patrick Nana-Sinkam
Journal:  Respir Med       Date:  2015-02-19       Impact factor: 3.415

10.  microRNA-141 inhibits thyroid cancer cell growth and metastasis by targeting insulin receptor substrate 2.

Authors:  Su Dong; Xianying Meng; Shuai Xue; Zewen Yan; Peiyou Ren; Jia Liu
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.